RESUMO
Tendinopathy is a common condition, which has been linked to surrogate measures of sympathetic nervous system (SNS) activity and insulin resistance. This study aimed to compare in vivo measures of the SNS and insulin resistance between individuals with and without Achilles tendinopathy. This case-control study compared Achilles tendinopathy sufferers to healthy controls. SNS activity was quantified using muscle sympathetic nerve activity (MSNA), while metabolic status was assessed via a modified glucose tolerance test and fasting lipid panel. Ultrasound tissue characterization assessed tendon structure. Resting MSNA did not differ between the 15 cases and 20 controls. Tendon pain duration in tendinopathy patients was correlated with burst frequency (R2 =.32, P=.02) and burst incidence (R2 =.41, P=.01) of MSNA. After adjusting for multiple comparisons, there was a trend suggesting fasting glucose was greater in cases (median 4.80, IQR .70 in cases vs 4.51, .38 in controls) and correlated with pain severity (R2 =.14, P=.03), but no other metabolic measures were associated with tendon pain/structure. This study indicates that SNS activity is associated with tendon pain duration, building on previous data indicating the SNS is involved in recalcitrant tendinopathy. Metabolic parameters had little relationship with Achilles tendinopathy in this metabolically homogenous sample. Prospective studies are required to uncover the precise relationship between SNS activity, insulin resistance, and tendinopathy.
Assuntos
Tendão do Calcâneo/fisiopatologia , Resistência à Insulina , Dor/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Tendinopatia/fisiopatologia , Tendão do Calcâneo/diagnóstico por imagem , Adulto , Estudos de Casos e Controles , Feminino , Teste de Tolerância a Glucose , Humanos , Masculino , Tendinopatia/diagnóstico por imagem , UltrassonografiaRESUMO
The opioid and cannabinoid systems play a crucial role in multiple physiological processes in the central nervous system and in the periphery. Selective opioid as well as cannabinoid (CB) receptor agonists exert a potent inhibitory action on gastrointestinal (GI) motility and pain. In this study, we examined (in vitro and in vivo) whether PR-38 (2-O-cinnamoylsalvinorin B), a novel analog of salvinorin A, can interact with both systems and demonstrate therapeutic effects. We used mouse models of hypermotility, diarrhea, and abdominal pain. We also assessed the influence of PR-38 on the central nervous system by measurement of motoric parameters and exploratory behaviors in mice. Subsequently, we investigated the pharmacokinetics of PR-38 in mouse blood samples after intraperitoneal and oral administration. PR-38 significantly inhibited mouse colonic motility in vitro and in vivo. Administration of PR-38 significantly prolonged the whole GI transit time, and this effect was mediated by µ- and κ-opioid receptors and the CB1 receptor. PR-38 reversed hypermotility and reduced pain in mouse models mimicking functional GI disorders. These data expand our understanding of the interactions between opioid and cannabinoid systems and their functions in the GI tract. We also provide a novel framework for the development of future potential treatments of functional GI disorders.
Assuntos
Dor Abdominal/tratamento farmacológico , Agonistas de Receptores de Canabinoides/farmacologia , Diterpenos Clerodânicos/uso terapêutico , Motilidade Gastrointestinal/efeitos dos fármacos , Síndrome do Intestino Irritável/tratamento farmacológico , Receptores Opioides kappa/antagonistas & inibidores , Receptores Opioides mu/agonistas , Dor Abdominal/complicações , Administração Oral , Animais , Antagonistas de Receptores de Canabinoides/farmacologia , Diarreia/complicações , Diarreia/tratamento farmacológico , Modelos Animais de Doenças , Diterpenos Clerodânicos/administração & dosagem , Diterpenos Clerodânicos/química , Diterpenos Clerodânicos/farmacologia , Relação Dose-Resposta a Droga , Comportamento Exploratório/efeitos dos fármacos , Injeções Intraperitoneais , Síndrome do Intestino Irritável/complicações , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Receptores Opioides mu/antagonistas & inibidoresRESUMO
AIM: Eosinophilic colitis (EC) is a rare manifestation of eosinophilic gastrointestinal disorders. Due to its rarity, little information is available on its natural history. METHOD: From the single population-based pathology database of the Calgary Health Region (comprising a population of 1.28 million in 2008), cases of EC during the period 1996-2008 were identified. Medical records of all adults diagnosed with EC were identified and the pathology reviewed. The patients were then contacted for follow-up using a standardized questionnaire. RESULTS: Seven cases of EC (four in women) were identified, with a median follow-up of 45 (23-79) months. The median age at diagnosis was 42 (22-70) years. Symptoms at diagnosis were abdominal pain (86%), nonbloody diarrhoea (57%), bloody diarrhoea (29%) and significant (>10%) weight loss (29%). Three patients gave a history of allergic reactions to drugs and four reported allergy to cows' milk. Endoscopic findings were nonspecific, ranging from oedema to small aphthous ulceration. An eosinophilic infiltrate was identified in the lamina propria in the initial colonic biopsy in all patients. Over the longer term, three patients experienced spontaneous resolution without treatment. Two continued to have mild diarrhoea and abdominal cramps but did not require medical therapy. Two patients required medical treatment by 5-aminosalicylic acid, with one requiring prednisone and azathioprine maintenance therapy. CONCLUSION: Eosinophilic colitis is a rare mostly self-limiting disease affecting middle-aged adults. It usually has a mild clinical course and drug treatment is not usually necessary. When required, drug treatment follows the standard medication for other inflammatory bowel disease.
Assuntos
Colite/diagnóstico , Colo/patologia , Eosinofilia/diagnóstico , Dor Abdominal/etiologia , Adulto , Idoso , Anti-Inflamatórios não Esteroides/uso terapêutico , Estudos de Coortes , Colite/complicações , Colite/tratamento farmacológico , Colonoscopia , Diarreia/etiologia , Progressão da Doença , Eosinofilia/complicações , Eosinofilia/tratamento farmacológico , Feminino , Seguimentos , Hemorragia Gastrointestinal/etiologia , Humanos , Masculino , Mesalamina/uso terapêutico , Pessoa de Meia-Idade , Remissão Espontânea , Estudos Retrospectivos , Redução de Peso , Adulto JovemRESUMO
Functional heartburn is a frequent disease which should be considered when heartburn does not respond to proton pump inhibitor (PPI) treatment. Functional heartburn is defined in the Rome-III-criteria. Differential diagnoses like gastroesophageal reflux disease (GERD), non erosive reflux disease (NERD) and hypertensive esophagus are diagnosed employing an endoscopy and a 24h-pH-study. Since clinical trials are lacking, treatment approaches are empirical. Successful treatment includes adequate information of the patient, identification of the cardinal symptom and setting of realistic goals.
Assuntos
Gastroenteropatias/diagnóstico , Gastroenteropatias/tratamento farmacológico , Azia/diagnóstico , Azia/tratamento farmacológico , Antidepressivos/efeitos adversos , Antidepressivos/uso terapêutico , Diagnóstico Diferencial , Resistência a Medicamentos , Dispepsia/diagnóstico , Dispepsia/tratamento farmacológico , Dispepsia/etiologia , Determinação da Acidez Gástrica , Refluxo Gastroesofágico/complicações , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/tratamento farmacológico , Gastroenteropatias/etiologia , Gastroscopia , Azia/etiologia , Educação de Pacientes como Assunto , Inibidores da Bomba de Prótons/uso terapêuticoRESUMO
The current recommendations on indications, technical performance, and interpretation of diagnostic techniques for oesophageal reflux update the German recommandations about 24 hour pH measurement of 2003. The recommendations encompass conventional pH measurement, wireless pH measurement, pH and impedance measurements, and bilirubin measurement (duodenogastro-oesophageal reflux).
Assuntos
Bilirrubina/sangue , Determinação da Acidez Gástrica , Gastroenterologia/normas , Refluxo Gastroesofágico/diagnóstico , Concentração de Íons de Hidrogênio , Pletismografia de Impedância/normas , Guias de Prática Clínica como Assunto , Alemanha , HumanosRESUMO
Diffuse esophageal spasm is a primary esophageal motility disorder. The prevalence is 3-10% in patients with dysphagia and treatment options are limited. This review summarizes the treatment of diffuse esophageal spasm, including pharmacotherapy, endoscopic treatment, and surgical treatment with a special focus on botulinum toxin injection. A PubMed search was performed to identify the literature using the search items diffuse esophageal spasm and treatment. Pharmacotherapy with smooth muscle relaxants, proton pump inhibitors, and antidepressants was suggested from small case series and uncontrolled clinical trials. Endoscopic injection of botulinum toxin is a well-studied treatment option and results in good symptomatic benefit in patients with diffuse esophageal spasm. Surgical treatment was reported in patients with very severe symptoms refractory to pharmacologic treatment. This article summarizes the present knowledge on the treatment of diffuse esophageal spasm with a special emphasis on botulinum toxin injection. Endoscopic injection of botulinum toxin is presently the best studied treatment option but many questions remain unanswered.